Boxer Capital Management, LLC
About Boxer Capital Management, LLC’s 13F portfolio
Boxer Capital Management, LLC is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Boxer Capital Management, LLC reported $1.3B across 63 US-listed positions (). Its largest position is TANGO THERAPEUTICS INC (TNGX) at 26% of the reported book, and its ten biggest holdings make up 65% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NASDAQ: TNGX TANGO THERAPEUTICS INC | — — | 26% | 10.9M | $340.0M |
| 2 | NASDAQ: RVMD REVOLUTION MEDICINES INC | — — | 7.1% | 500K | $93.6M |
| 3 | NASDAQ: ABVX ABIVAX SA | — — | 6.1% | 605K | $80.6M |
| 4 | NASDAQ: QURE UNIQURE NV | — — | 5.2% | 1.5M | $69.2M |
| 5 | NASDAQ: KOD KODIAK SCIENCES INC | — — | 4.3% | 1.5M | $57.6M |
| 6 | NASDAQ: KYMR KYMERA THERAPEUTICS INC | — — | 3.7% | 429K | $49.2M |
| 7 | NASDAQ: DFTX DEFINIUM THERAPEUTICS INC | — — | 3.5% | 999K | $47.0M |
| 8 | NASDAQ: REPL REPLIMUNE GROUP INC | — — | 3.3% | 4.0M | $44.1M |
| 9 | NASDAQ: CELC CELCUITY INC | — — | 3.3% | 417K | $43.6M |
| 10 | NASDAQ: QTTB Q32 BIO INC | — — | 3.0% | 3.1M | $40.1M |
| 11 | NASDAQ: CAPR CAPRICOR THERAPEUTICS INC | — — | 2.5% | 1.4M | $33.6M |
| 12 | NASDAQ: PGEN PRECIGEN INC | — — | 2.2% | 5.2M | $29.4M |
| 13 | NASDAQ: CORT CORCEPT THERAPEUTICS INC | — — | 2.2% | 336K | $29.2M |
| 14 | NASDAQ: SRZN Surrozen Inc. | — — | 2.0% | 1.1M | $27.0M |
| 15 | NASDAQ: PTGX PROTAGONIST THERAPEUTICS INC | — — | 1.6% | 170K | $20.8M |
| 16 | NASDAQ: VIR VIR BIOTECHNOLOGY INC | — — | 1.4% | 1.9M | $19.0M |
| 17 | NASDAQ: PCVX VAXCYTE INC | — — | 1.4% | 325K | $18.9M |
| 18 | NASDAQ: URGN UROGEN PHARMA LTD | — — | 1.4% | 500K | $18.4M |
| 19 | NASDAQ: CRVS CORVUS PHARMACEUTICALS INC | — — | 1.2% | 1.1M | $16.4M |
| 20 | NASDAQ: PTCT PTC THERAPEUTICS INC | — — | 1.2% | 200K | $16.3M |
| 21 | NASDAQ: PRAX PRAXIS PRECISION MEDICINES I | — — | 1.2% | 46K | $15.6M |
| 22 | NASDAQ: AMLX AMYLYX PHARMACEUTICALS INC | — — | 1.1% | 800K | $14.4M |
| 23 | NASDAQ: OCUL OCULAR THERAPEUTIX INC | — — | 1.0% | 1.3M | $12.8M |
| 24 | NASDAQ: IRD OPUS GENETICS INC | — — | 0.9% | 2.8M | $11.6M |
| 25 | NASDAQ: PALI PALISADE BIO INC | — — | 0.8% | 4.8M | $10.0M |
Showing 1–25 of 63 positions on this page reported in this 13F.
- Healthcare95%
- Consumer Defensive0.2%
- AddedABVXABIVAX SA+203%$80.6M
- AddedQUREUNIQURE NV+127%$69.2M
- AddedKODKODIAK SCIENCES INC+8.6%$57.6M
- AddedKYMRKYMERA THERAPEUTICS INC+30.4%$49.2M
- AddedDFTXDEFINIUM THERAPEUTICS INC+66.8%$47.0M
- AddedREPLREPLIMUNE GROUP INC+239%$44.1M
- AddedCELCCELCUITY INC+85.1%$43.6M
- NewQTTBQ32 BIO INC—$40.1M
- AddedCAPRCAPRICOR THERAPEUTICS INC+136%$33.6M
- AddedPGENPRECIGEN INC+47.1%$29.4M
- ReducedALLOALLOGENE THERAPEUTICS INC−45.0%$3.1M
- SoldSLNOSOLENO THERAPEUTICS INC−100%—
- SoldTERNTERNS PHARMACEUTICALS INC−100%—
- SoldKALVKALVISTA PHARMACEUTICALS INC−100%—
Reading Boxer Capital Management, LLC’s 13F portfolio
Boxer Capital Management, LLC’s $1.3B 13F book is spread across 63 reported positions and is highly concentrated — its ten largest positions alone are 65% of the portfolio. A book this concentrated means a small group of names drives most of its performance. Its five largest positions are TNGX, RVMD, ABVX, QURE and KOD, led by TANGO THERAPEUTICS INC (TNGX) at 26% of the portfolio. The heaviest sector exposure is Healthcare (95%), then Consumer Defensive (0%).
What Boxer Capital Management, LLC changed last quarter
Between 2026-03-31 and Q2 2026, Boxer Capital Management, LLC was a net buyer: it opened 12 new positions and added to 17 more, while trimming 1 and closing 3 outright. Against a 63-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was ABIVAX SA (ABVX), and its biggest reduction was ALLOGENE THERAPEUTICS INC (ALLO).
What a 13F does and doesn’t reveal
A 13F captures only Boxer Capital Management, LLC’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Boxer Capital Management, LLC is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Boxer Capital Management, LLC's profile on this page is built directly from those filings.
How current is the 13F data on Boxer Capital Management, LLC's page?
It reflects Boxer Capital Management, LLC's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Boxer Capital Management, LLC files its next quarterly report, this page refreshes automatically.
Can I see Boxer Capital Management, LLC's complete list of holdings?
This page highlights Boxer Capital Management, LLC's largest positions rather than all 63 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Boxer Capital Management, LLC's filings.
Does a 13F show everything Boxer Capital Management, LLC owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Boxer Capital Management, LLC's book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Boxer Capital Management, LLC made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

